Bali Muralidhar
InvestorManaging Partner at Abingworth
London
Writes $15M β $30M checks Β· typically $22.5M
About
Bali Muralidhar has more than 20 years of healthcare experience spanning venture investing, R&D, clinical practice, and teaching. At Abingworth he leads the transatlantic venture and clinical co-development investment teams and chairs the firm's investment committees. He previously was a senior partner at MVM Partners in London and a member of Bain Capital's healthcare deal team. He holds a degree in clinical medicine from the University of Oxford, practiced general surgery, and earned a PhD in translational cancer research from the University of Cambridge.
Invests in
BiotechHealthtech
Experience
- AbingworthGlobal Head of Life Sciencescurrent2026 β present
- AbingworthManaging Partner, Chief Investment Officercurrent2022 β present
- AbingworthManaging Partnercurrent2020 β presentLondon, United Kingdom
- AbingworthPartner2019 β 2020
- British Business BankNon Executive Directorcurrent2025 β presentLondon, United Kingdom
- MVM PartnersPartner2012 β 2019London, United Kingdom
- Bain CapitalAssociate2011 β 2012
- Bain & CompanyConsultant2008 β 2011
- University of Cambridge, Downing CollegeBye-Fellow2006 β 2008
- Medical Reseach CouncilResearcher2005 β 2008Translational Cancer Cell Unit - Cambridge University
- National Health ServiceClinical Fellow2004 β 2008Cambridge, United Kingdom
Education
- University of CambridgePhD, Cancer biology2005 β 2008
- University of OxfordBMBCh, Clinical medicine2001 β 2004
- University of CambridgeMA, Medical Science1998 β 2001
Skills & more
+4 more
Start-upsLife SciencesMergers & AcquisitionsPharmaceutical IndustryFrom Bali's professional profile.
Same school
Also attended University of Cambridge621
+ 615 more
Also attended University of Oxford687
+ 681 more
Shared employers
Also worked at Abingworth17
+ 11 more
Also worked at MVM Partners2
Deals Β· 5
Allotera Therapeutics, Inc.Board seat
via Abingworth Β· filed Jul 2026 Β· $163M raise
AdvanCellBoard seat
via Abingworth Β· filed Jul 2026 Β· $315M raise
Spruce Biosciences IncBoard seat
via Abingworth Β· filed Oct 2025 Β· $50M raise
WugenBoard seat
via Abingworth Β· filed Jul 2021 Β· $37.2M raise
Onkure Therapeutics IncBoard seat
via Abingworth Β· filed Dec 2020 Β· $94.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Abingworth
Network5
Investors connected to Bali in public investor directories β a warm-intro map.

.png)































